Arcellx, Inc. ACLX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

32/100

0/7 Pass

SharesGrow Intrinsic Value

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Arcellx, Inc. (ACLX) has a negative trailing P/E of -28.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 292.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -3.54%, forward earnings yield 0.34%. PEG 0.87 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

VALUE (57/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
Forward P/E 292.0 — analysts expect a return to profitability with estimated EPS of $0.39 for FY2028.
PEG Ratio 0.87 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
Trailing Earnings Yield -3.54% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 0.34% as earnings recover.
Analyst consensus target $110.42 (-3.9% downside) — slight downside risk — the market may be ahead of analyst expectations.

Overall SharesGrow Score: 32/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

32/100

SG Score

View full scorecard →

VALUE

57/100

Price-to-Earnings & upside

Proven by this page

✗

FUTURE

26/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

→ Health

MOAT

47/100

→ Income

✗

GROWTH

15/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — ACLX

Valuation Multiples

P/E (TTM)-28.2

Forward P/E292.0

PEG Ratio0.87

Forward PEG0.87

P/B Ratio16.07

P/S Ratio301.24

EV/EBITDA-34.0

Per Share Data

EPS (TTM)$-4.07

Forward EPS (Est.)$0.39

Book Value / Share$7.15

Revenue / Share$0.40

FCF / Share$-3.78

Yields & Fair Value

Earnings Yield-3.54%

Forward Earnings Yield0.34%

Dividend Yield0.00%

Analyst Target$110.42 (-3.9%)

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	P/S Ratio	Dividend Yield
2018	-0.3	0.00	0.20	0.00	-
2019	-32.5	0.33	-17.85	0.00	-
2020	-11.4	-0.06	7.24	0.00	-
2021	-8.7	-0.27	-4.64	0.00	-
2022	-7.2	-0.06	6.67	0.00	-
2023	-37.7	0.57	5.50	24.18	-
2024	-38.3	-1.06	9.03	38.06	-
2025	-16.0	-0.15	9.12	164.73	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2018	$-50.17	$0.00	$-8.31M	-
2019	$-0.52	$0.00	$-17.97M	-
2020	$-1.47	$0.00	$-32.1M	-
2021	$-1.91	$0.00	$-63.93M	-
2022	$-4.22	$0.00	$-186.1M	-
2023	$-1.47	$110.32M	$-70.69M	-64.1%
2024	$-2.00	$107.94M	$-107.35M	-99.5%
2025	$-4.07	$22.29M	$-228.93M	-1027.3%

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$-3.71	$-6.17 – $-0.29	$73.66M	$17.67M – $159.24M	8
2027	$-1.71	$-6.68 – $2.27	$261.94M	$203.44M – $306.52M	9
2028	$0.41	$-0.59 – $1.50	$467.4M	$462.39M – $472.41M	10
2029	$3.87	$1.48 – $7.74	$742.69M	$390.04M – $1.31B	4
2030	$7.42	$2.84 – $14.82	$1.08B	$567.51M – $1.91B	4